Hepatic SIRT6 protects against cholestatic liver disease primarily via inhibiting bile acid synthesis

Abstract

Cholestatic liver disease, caused by the accumulation of hazardous bile acids in the liver, may result in cirrhosis, fibrosis, or liver failure. Activation of sirtuin 6 (SIRT6) prevents cholestasis-associated pathological events, such as oxidative stress and mitochondrial biogenesis dysfunction, and inhibits bile acid synthesis to alleviate cholestatic liver injury. However, it remains uncertain which pathway mediates the therapeutic effect of SIRT6 in reducing cholestasis. Therefore, we treated liver-specific Sirt6 knockout mice with N-acetylcysteine, KEAP1-NRF2-IN-1, or acadesine to alleviate oxidative stress and/or promote mitochondrial biogenesis after modeling cholestatic liver disease, but these measures did not significantly improve cholestatic symptoms. However, MDL801, a SIRT6 agonist that downregulates cholesterol 7α-hydroxylase (CYP7A1, the key enzyme in bile acid synthesis) levels, exhibited favorable therapeutic effects. Additionally, the hepatic knockdown of Cyp7a1 further demonstrated that inhibiting hepatic bile acid synthesis might be the main pathway through which SIRT6 alleviates cholestatic liver disease. These findings provide a solid basis for the potential application of SIRT6 agonists in treating cholestatic liver disease.

Keywords

sirtuin 6 / cholestatic liver disease / oxidative stress / mitochondrial biogenesis / bile acid synthesis

Fundings

This work was supported by the National Natural Science Foundation of China (Grant No. 82170877).

Acknowledgments

None.

References

[1] Cai S, Boyer JL. The role of bile acids in cholestatic liver injury[J]. Ann Transl Med, 2021, 9(8): 737. doi: 10.21037/atm-20-5110

[2] Anthérieu S, Azzi PBE, Dumont J, et al. Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells[J]. Hepatology, 2013, 57(4): 1518-1529. doi: 10.1002/hep.26160

[3] Rolo AP, Palmeira CM, Wallace KB. Mitochondrially mediated synergistic cell killing by bile acids[J]. Biochim Biophys Acta Mol Basis Dis, 2003, 1637(1): 127-132. doi: 10.1016/S0925-4439(02)00224-7

[4] Kujoth GC, Hiona A, Pugh TD, et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging[J]. Science, 2005, 309(5733): 481-484. doi: 10.1126/science.1112125

[5] Yang JL, Weissman L, Bohr VA, et al. Mitochondrial DNA damage and repair in neurodegenerative disorders[J]. DNA Repair (Amst), 2008, 7(7): 1110-1120. doi: 10.1016/j.dnarep.2008.03.012

[6] Wallace DC. Mitochondrial diseases in man and mouse[J]. Science, 1999, 283(5407): 1482-1488. doi: 10.1126/science.283.5407.1482

[7] Tidwell J, Wu GY. Heritable chronic cholestatic liver diseases: A review[J]. J Clin Transl Hepatol, 2024, 12(8): 726-738.

[8] Luo X, Lu L. Progress in the management of patients with cholestatic liver disease: Where are we and where are we going?[J]. J Clin Transl Hepatol, 2024, 12(6): 581-588. doi: 10.14218/JCTH.2023.00519

[9] Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis[J]. Lancet, 2015, 386(10003): 1565-1575. doi: 10.1016/S0140-6736(15)00154-3

[10] Jiang H, Khan S, Wang Y, et al. SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine[J]. Nature, 2013, 496(7443): 110-113. doi: 10.1038/nature12038

[11] Liszt G, Ford E, Kurtev M, et al. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase[J]. J Biol Chem, 2005, 280(22): 21313-21320. doi: 10.1074/jbc.M413296200

[12] Liu G, Chen H, Liu H, et al. Emerging roles of SIRT6 in human diseases and its modulators[J]. Med Res Rev, 2021, 41(2): 1089-1137. doi: 10.1002/med.21753

[13] Ka SO, Bang IH, Bae EJ, et al. Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor[J]. FASEB J, 2017, 31(9): 3999-4010. doi: 10.1096/fj.201700098RR

[14] Zhou Y, Fan X, Jiao T, et al. SIRT6 as a key event linking P53 and NRF2 counteracts APAP-induced hepatotoxicity through inhibiting oxidative stress and promoting hepatocyte proliferation[J]. Acta Pharm Sin B, 2021, 11(1): 89-99. doi: 10.1016/j.apsb.2020.06.016

[15] Liu X, Ren S, Li Z, et al. Sirt6 mediates antioxidative functions by increasing Nrf2 abundance[J]. Exp Cell Res, 2023, 422(1): 113409. doi: 10.1016/j.yexcr.2022.113409

[16] Liu C, Pan Z, Wu Z, et al. Hepatic SIRT6 modulates transcriptional activities of FXR to alleviate acetaminophen-induced hepatotoxicity[J]. Cell Mol Gastroenterol Hepatol, 2022, 14(2): 271-293. doi: 10.1016/j.jcmgh.2022.04.011

[17] Li J, Yu D, Chen S, et al. Sirt6 opposes glycochenodeoxycholate-induced apoptosis of biliary epithelial cells through the AMPK/PGC-1α pathway[J]. Cell Biosci, 2020, 10(1): 43. doi: 10.1186/s13578-020-00402-6

[18] Yu L, Dong X, Xue X, et al. Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to ischemia-reperfusion injury by improving mitochondrial quality control: Role of SIRT6[J]. J Pineal Res, 2021, 70(1): e12698. doi: 10.1111/jpi.12698

[19] Smirnov D, Eremenko E, Stein D, et al. SIRT6 is a key regulator of mitochondrial function in the brain[J]. Cell Death Dis, 2023, 14(1): 35. doi: 10.1038/s41419-022-05542-w

[20] Hao L, Bang IH, Wang J, et al. ERRγ suppression by Sirt6 alleviates cholestatic liver injury and fibrosis[J]. JCI Insight, 2020, 5(17): e137566. doi: 10.1172/jci.insight.137566

[21] Świętek M, Marková I, Malínská H, et al. Tannic acid- and N-acetylcysteine-chitosan-modified magnetic nanoparticles reduce hepatic oxidative stress in prediabetic rats[J]. Colloids Surf B Biointerfaces, 2024, 235: 113791. doi: 10.1016/j.colsurfb.2024.113791

[22] Lu M, Zhang X, Wu F, et al. Discovery of a potent kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) protein-protein interaction inhibitor with natural proline structure as a cytoprotective agent against acetaminophen-induced hepatotoxicity[J]. J Med Chem, 2019, 62(14): 6796-6813. doi: 10.1021/acs.jmedchem.9b00818

[23] Hinkle JS, Rivera CN, Vaughan RA. AICAR stimulates mitochondrial biogenesis and BCAA catabolic enzyme expression in C2C12 myotubes[J]. Biochimie, 2022, 195: 77-85. doi: 10.1016/j.biochi.2021.11.004

[24] Tang C, Liu P, Zhou Y, et al. Sirt6 deletion in hepatocytes increases insulin sensitivity of female mice by enhancing ERα expression[J]. J Cell Physiol, 2019, 234(10): 18615-18625. doi: 10.1002/jcp.28500

[25] Zhang Y, Hong JY, Rockwell CE, et al. Effect of bile duct ligation on bile acid composition in mouse serum and liver[J]. Liver Int, 2012, 32(1): 58-69. doi: 10.1111/j.1478-3231.2011.02662.x

[26] Andreani C, Bartolacci C, Guescini M, et al. Combination of coenzyme Q₁₀ intake and moderate physical activity counteracts mitochondrial dysfunctions in a SAMP8 mouse model[J]. Oxid Med Cell Longev, 2018, 2018(1): 8936251. doi: 10.1155/2018/8936251

[27] Sheng L, Zhou Y, Chen Z, et al. NF-κB-inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action[J]. Nat Med, 2012, 18(6): 943-949. doi: 10.1038/nm.2756

[28] Ni X, Wang H, Cai Y, et al. Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke[J]. Redox Biol, 2022, 54: 102363. doi: 10.1016/j.redox.2022.102363

[29] Arduini A, Serviddio G, Escobar J, et al. Mitochondrial biogenesis fails in secondary biliary cirrhosis in rats leading to mitochondrial DNA depletion and deletions[J]. Am J Physiol Gastrointest Liver Physiol, 2011, 301(1): G119-G127. doi: 10.1152/ajpgi.00253.2010

[30] Orozco-Aguilar J, Simon F, Cabello-Verrugio C. Redox-dependent effects in the physiopathological role of bile acids[J]. Oxid Med Cell Longev, 2021, 2021(1): 4847941. doi: 10.1155/2021/4847941

[31] Rodrigues CM, Steer CJ. Mitochondrial membrane perturbations in cholestasis[J]. J Hepatol, 2000, 32(1): 135-141.

[32] Malik N, Ferreira BI, Hollstein PE, et al. Induction of lysosomal and mitochondrial biogenesis by AMPK phosphorylation of FNIP1[J]. Science, 2023, 380(6642): eabj5559. doi: 10.1126/science.abj5559

[33] Yoon YG, Koob MD, Yoo YH. Mitochondrial genome-maintaining activity of mouse mitochondrial transcription factor A and its transcript isoform in Saccharomyces cerevisiae[J]. Gene, 2011, 484(1-2): 52-60. doi: 10.1016/j.gene.2011.05.032

[34] Campbell CT, Kolesar JE, Kaufman BA. Mitochondrial transcription factor A regulates mitochondrial transcription initiation, DNA packaging, and genome copy number[J]. Biochim Biophys Acta Gene Regul Mech, 2012, 1819(9-10): 921-929. doi: 10.1016/j.bbagrm.2012.03.002

[35] Xu S, Chen Y, Lin H, et al. Damage to mtDNA in liver injury of patients with extrahepatic cholestasis: The protective effects of mitochondrial transcription factor A[J]. Free Radic Biol Med, 2012, 52(9): 1543-1551. doi: 10.1016/j.freeradbiomed.2012.01.007

[36] Liu H, Pathak P, Boehme S, et al. Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis[J]. J Lipid Res, 2016, 57(10): 1831-1844. doi: 10.1194/jlr.M069807

[37] Nevens F, Trauner M, Manns MP. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases[J]. J Hepatol, 2023, 78(2): 430-441. doi: 10.1016/j.jhep.2022.10.007

[38] Chanda D, Xie Y, Choi HS. Transcriptional corepressor SHP recruits SIRT1 histone deacetylase to inhibit LRH-1 transactivation[J]. Nucleic Acids Res, 2010, 38(14): 4607-4619. doi: 10.1093/nar/gkq227

[39] Kir S, Zhang Y, Gerard RD, et al. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo[J]. J Biol Chem, 2012, 287(49): 41334-41341. doi: 10.1074/jbc.M112.421834

[40] Wang Y, Gunewardena S, Li F, et al. An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis[J]. Nat Commun, 2020, 11(1): 3612. doi: 10.1038/s41467-020-17363-6

[41] Gbaguidi GF, Agellon LB. The inhibition of the human cholesterol 7α-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor α and peroxisome proliferator-activated receptor α heterodimer[J]. Nucleic Acids Res, 2004, 32(3): 1113-1121. doi: 10.1093/nar/gkh260

[42] Wahlström A, Sayin SI, Marschall HU, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism[J]. Cell Metab, 2016, 24(1): 41-50. doi: 10.1016/j.cmet.2016.05.005